Roche (RHHBF) unit Genentech posts encouraging late-stage trial data for its breast cancer drug giredestrant noting up to 62% ...
Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.
In "We Survived the Night," NoiseCat touches on family history, community, and Indigenous life across North America.
PowerUp Gamer on MSN
Endless Horde Codes – October 2025
Looking for the latest Endless Horde codes? We’ve got you covered! This list includes all of the active… The post Endless Horde Codes – October 2025 first appeared on PowerUp Gamer.
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free ...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard- ...
New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer ...
Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...
For children born with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), an investigational ...
Alpha Prime is a sci-fi shooter from Black Element Software. Explore an abandoned asteroid, fight robots, survive in space ...
Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo ...
BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results